



IFW

PATENT--NO FEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:) I hereby certify that this
ANIL GULATI) paper is being deposited
Serial No.: 10/691,915) with the United States
Filed: October 23, 2003) Postal Service with suffi-
For: METHOD AND COMPOSITION FOR) cient postage, as first
PREVENTING AND TREATING SOLID) class mail, in an envelope
TUMORS) addressed to:
Attorney Docket No. 27611/38802A) Commissioner for Patents
Group Art Unit: 1614) P.O. Box 1450
Examiner: Unassigned) Alexandria, VA 22313-1450
Dated: May 27, 2004
James J. Napoli
Registration No. 32,361
Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Pursuant to his duty of disclosure under 37 C.F.R. §1.56, applicant hereby brings to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicant encloses a completed Form PTO-1449 listing the possible pertinent patents and publications and a copy of each non-U.S. patent and publication.

This Supplemental Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and,

to applicants' knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Supplemental Information Disclosure Statement shall be considered by the Patent Office.

In addition, if a first Office Action has been mailed, each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement (37 C.F.R. §1.97(e)(1)). Accordingly, no fee as set forth in 37 C.F.R. §1.17(p) is due.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

A copy of the International Search Report is enclosed for the convenience of the examiner and to complete the file. Two references cited in the International Search Report are not cited in this Supplemental Information Disclosure Statement. These references were cited in the Information Disclosure Statement mailed on March 19, 2004.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

By

A handwritten signature in black ink, appearing to read "James J. Napoli", is written over a horizontal line.

James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
May 27, 2004



Form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/691,915
				Filing Date	October 23, 2003
				First Named Inventor	Anil Gulati
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	27611/38802A

U.S. PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY
		5,550,110	08/27/1996

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY
		WO 00/67024 (PCT)	11/09/2000
		WO 01/00198 (PCT)	01/04/2001
		0 655 463 (EP)	05/31/1995
		0 950 418 (EP)	10/20/1999

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		K. Kikuchi et al., <i>Biochemical and Biophysical Research Communications</i> , Vol. 219, No. 3, 734-739 (1996).
		A. Rai et al., <i>Cancer Chemother. Pharmacol.</i> , Vol. 51, 21-28 (2002).
		R. Lahav et al., <i>Proceedings of the National Academy of Sciences of USA</i> , Vol. 96, 11496-11500 (1999).
		K.M. Bell et al., <i>Journal of Cardiovascular Pharmacology</i> , Vol. 26, No. s3, s222-s225 (1995).
		D. DelBufalo et al., <i>Clinical Science</i> , Vol. 103, No. S48, 302S-305S (2002).
		J.M. Kroodsma et al., <i>Nederlands Tijdschrift Voor Geneeskunde</i> , Vol. 141, No. 38, 1-3 (1997).
		B. Battistini et al., <i>Drug News & Perspectives</i> , Vol. 8, No. 6, 365-391 (1995).
		A.P. Davenport et al., <i>Clinical Science</i> , Vol. 103, No. S48, 1S-3S (2002).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.